益丰药房
(603939)
| 流通市值：272.55亿 | | | 总市值：272.55亿 |
| 流通股本：12.12亿 | | | 总股本：12.12亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 12,129,983,982.07 | 6,085,003,538.59 | 24,433,165,197.5 | 17,285,899,932.64 |
| 营业收入 | 12,129,983,982.07 | 6,085,003,538.59 | 24,433,165,197.5 | 17,285,899,932.64 |
| 二、营业总成本 | 10,737,842,732.39 | 5,386,162,931.81 | 22,129,134,049.16 | 15,631,502,380.85 |
| 营业成本 | 7,241,974,262.94 | 3,648,783,760.21 | 14,817,330,076.73 | 10,301,538,874.58 |
| 税金及附加 | 55,665,651.66 | 24,403,091.5 | 100,913,544.6 | 70,718,352.18 |
| 销售费用 | 2,825,257,795.3 | 1,368,576,218.51 | 5,854,321,676.31 | 4,314,047,379.82 |
| 管理费用 | 546,812,603.43 | 310,563,885.07 | 1,186,590,030.12 | 810,664,430.34 |
| 研发费用 | 11,553,736.13 | 5,853,144.25 | 27,916,037 | 21,511,803.3 |
| 财务费用 | 56,578,682.93 | 27,982,832.27 | 142,062,684.4 | 113,021,540.63 |
| 其中:利息费用 | 65,870,504.65 | 31,846,152.06 | 166,753,646.09 | 142,596,906.53 |
| 其中:利息收入 | 16,574,159.78 | 7,465,366.97 | 47,517,011.03 | 46,842,510.68 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 56,272,544.79 | 27,767,028.59 | 124,747,936.19 | 99,769,501.43 |
| 资产处置收益 | 23,206,570.32 | 11,356,506.77 | 68,481,322.52 | 48,837,520.02 |
| 资产减值损失(新) | -46,632,781.15 | -23,740,937.33 | -111,612,199.85 | -71,649,596.76 |
| 信用减值损失(新) | -3,403,083.41 | -1,225,635.45 | -36,992.73 | 2,686,362.71 |
| 其他收益 | 25,058,020.44 | 14,667,331.01 | 68,112,555.33 | 52,760,114.25 |
| 四、营业利润 | 1,446,642,520.67 | 727,664,900.37 | 2,453,723,769.8 | 1,786,801,453.44 |
| 加:营业外收入 | 15,420,402.26 | 2,133,912.01 | 37,754,018.54 | 6,951,356.21 |
| 减:营业外支出 | 20,293,528.88 | 6,159,025.24 | 35,082,935.93 | 23,797,122.37 |
| 五、利润总额 | 1,441,769,394.05 | 723,639,787.14 | 2,456,394,852.41 | 1,769,955,687.28 |
| 减:所得税费用 | 372,701,751.97 | 177,554,652.98 | 625,369,295.81 | 448,789,079.56 |
| 六、净利润 | 1,069,067,642.08 | 546,085,134.16 | 1,831,025,556.6 | 1,321,166,607.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,069,067,642.08 | 546,085,134.16 | 1,831,025,556.6 | 1,321,166,607.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 963,777,247.55 | 499,549,828.27 | 1,678,481,865.01 | 1,224,555,838.55 |
| 少数股东损益 | 105,290,394.53 | 46,535,305.89 | 152,543,691.59 | 96,610,769.17 |
| 扣除非经常损益后的净利润 | 951,919,761.46 | 493,053,446.12 | 1,611,562,235.26 | 1,187,922,925.11 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.79 | 0.41 | 1.38 | 1.01 |
| (二)稀释每股收益 | 0.78 | 0.4 | 1.36 | 0.99 |
| 八、其他综合收益 | - | - | 75,076,268.99 | 47,773,490.51 |
| 归属于母公司股东的其他综合收益 | - | - | 75,076,268.99 | 47,773,490.51 |
| 九、综合收益总额 | 1,069,067,642.08 | 546,085,134.16 | 1,906,101,825.59 | 1,368,940,098.23 |
| 归属于母公司股东的综合收益总额 | 963,777,247.55 | 499,549,828.27 | 1,753,558,134 | 1,272,329,329.06 |
| 归属于少数股东的综合收益总额 | 105,290,394.53 | 46,535,305.89 | 152,543,691.59 | 96,610,769.17 |
| 公告日期 | 2026-08-28 | 2026-04-23 | 2026-04-23 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |